Biomarkers for living donor liver transplants in hepatocellular carcinoma

Edward Butt; Rupak Kulkarni; Akshata Moghe

doi:10.20517/2394-5079.2023.25

Biomarkers for living donor liver transplants in hepatocellular carcinoma

Edward Butt, Rupak Kulkarni, Akshata Moghe

Research output: Contribution to journal › Review article › peer-review

Abstract

Liver transplantation is one of the more definitive treatments for hepatocellular carcinoma (HCC). In the United States, liver transplantation has historically been focused on deceased donor organs, and tumor burden is used for risk-stratifying patients on the transplant waitlist. Living donor liver transplantation (LDLT) is gaining popularity in the United States and has long been practiced in Asian countries. To improve outcomes of overall survival and disease-free survival post-living donor liver transplantation, surrogates of tumor biology are now being regarded to be as important as tumor burden. This article reviews the different surrogates of tumor biology and discusses their role in the application of LDLT for advanced HCC.

Original language	English (US)
Article number	20
Journal	Hepatoma Research
Volume	9
DOIs	https://doi.org/10.20517/2394-5079.2023.25
State	Published - 2023

Keywords

HCC
LDLT
tumor biology

ASJC Scopus subject areas

Hepatology
Oncology

Access to Document

10.20517/2394-5079.2023.25

Cite this

@article{fdf993bae0834bf98acf06dfa1199a92,

title = "Biomarkers for living donor liver transplants in hepatocellular carcinoma",

abstract = "Liver transplantation is one of the more definitive treatments for hepatocellular carcinoma (HCC). In the United States, liver transplantation has historically been focused on deceased donor organs, and tumor burden is used for risk-stratifying patients on the transplant waitlist. Living donor liver transplantation (LDLT) is gaining popularity in the United States and has long been practiced in Asian countries. To improve outcomes of overall survival and disease-free survival post-living donor liver transplantation, surrogates of tumor biology are now being regarded to be as important as tumor burden. This article reviews the different surrogates of tumor biology and discusses their role in the application of LDLT for advanced HCC.",

keywords = "HCC, LDLT, tumor biology",

author = "Edward Butt and Rupak Kulkarni and Akshata Moghe",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

doi = "10.20517/2394-5079.2023.25",

language = "English (US)",

volume = "9",

journal = "Hepatoma Research",

issn = "2394-5079",

publisher = "OAE Publishing Inc.",

}

TY - JOUR

T1 - Biomarkers for living donor liver transplants in hepatocellular carcinoma

AU - Butt, Edward

AU - Kulkarni, Rupak

AU - Moghe, Akshata

N1 - Publisher Copyright: © The Author(s) 2023.

PY - 2023

Y1 - 2023

N2 - Liver transplantation is one of the more definitive treatments for hepatocellular carcinoma (HCC). In the United States, liver transplantation has historically been focused on deceased donor organs, and tumor burden is used for risk-stratifying patients on the transplant waitlist. Living donor liver transplantation (LDLT) is gaining popularity in the United States and has long been practiced in Asian countries. To improve outcomes of overall survival and disease-free survival post-living donor liver transplantation, surrogates of tumor biology are now being regarded to be as important as tumor burden. This article reviews the different surrogates of tumor biology and discusses their role in the application of LDLT for advanced HCC.

AB - Liver transplantation is one of the more definitive treatments for hepatocellular carcinoma (HCC). In the United States, liver transplantation has historically been focused on deceased donor organs, and tumor burden is used for risk-stratifying patients on the transplant waitlist. Living donor liver transplantation (LDLT) is gaining popularity in the United States and has long been practiced in Asian countries. To improve outcomes of overall survival and disease-free survival post-living donor liver transplantation, surrogates of tumor biology are now being regarded to be as important as tumor burden. This article reviews the different surrogates of tumor biology and discusses their role in the application of LDLT for advanced HCC.

KW - HCC

KW - LDLT

KW - tumor biology

UR - http://www.scopus.com/inward/record.url?scp=85161442381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161442381&partnerID=8YFLogxK

U2 - 10.20517/2394-5079.2023.25

DO - 10.20517/2394-5079.2023.25

M3 - Review article

AN - SCOPUS:85161442381

SN - 2394-5079

VL - 9

JO - Hepatoma Research

JF - Hepatoma Research

M1 - 20

ER -

Biomarkers for living donor liver transplants in hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this